Thai Nguyen

Simplification to coformulated elvitegravir, cobicistat, emtricitabine, and tenofovir versus continuation of ritonavir-boosted protease inhibitor with emtricitabine and tenofovir in adults with virologically suppressed HIV (STRATEGY-PI): 48 week results of a randomised, open-label, phase 3b, non-inferiority trial

José Ramón Arribas, Gilles Pialoux, Joseph Gathe et al. · The Lancet Infectious Diseases · 2014 · 116 citations

Pharmacy, Infectious Diseases, Pharmacotherapy +17

Switching to coformulated elvitegravir, cobicistat, emtricitabine, and tenofovir versus continuation of non-nucleoside reverse transcriptase inhibitor with emtricitabine and tenofovir in virologically suppressed adults with HIV (STRATEGY-NNRTI): 48 week results of a randomised, open-label, phase 3b non-inferiority trial

Anton Pozniak, Martin Markowitz, Anthony Mills et al. · The Lancet Infectious Diseases · 2014 · 99 citations · Full text

Pharmacy, Infectious Diseases, Pharmacotherapy +17

Drug Interactions with Cobicistat- or Ritonavir-Boosted Elvitegravir.

Thai Nguyen, Ian R. McNicholl, Joseph M. Custodio et al. · PubMed · 2017 · 23 citations

Medicine, Pharmacokinetics, Pharmacology +17

Simplification to single-tablet regimen of elvitegravir, cobicistat, emtricitabine, tenofovir DF from multi-tablet ritonavir-boosted protease inhibitor plus coformulated emtricitabine and tenofovir DF regimens: week 96 results of STRATEGY-PI

José Ramón Arribas, Edwin DeJesus, Jan van Lunzen et al. · HIV Clinical Trials · 2017 · 16 citations

Pharmacy, Pharmacokinetics, Pharmacotherapy +17

Patient-Reported Symptoms Over 48 Weeks in a Randomized, Open-Label, Phase IIIb Non-Inferiority Trial of Adults with HIV Switching to Co-Formulated Elvitegravir, Cobicistat, Emtricitabine, and Tenofovir DF versus Continuation of Non-Nucleoside Reverse Transcriptase Inhibitor with Emtricitabine and Tenofovir DF

Anthony Mills, Will Garner, Anton Pozniak et al. · Patient · 2015 · 14 citations · Full text

Pharmacy, Pharmacology, Pharmacotherapy +17